The ASCO data are incremental and do not change the near-term regulatory or commercial outlook. Monitor the POLARIS-2 and GLORA phase 3 readouts for olverembatinib and lisaftoclax, which are the key catalysts.
Price Chart
Executive Summary
Ascentage Pharma announced that six abstracts from its clinical studies were selected for presentation at the 2026 ASCO Annual Meeting, including three rapid oral presentations. The abstracts cover data on its three lead drug candidates: olverembatinib (BCR-ABL inhibitor), lisaftoclax (Bcl-2 inhibitor), and alrizomadlin (MDM2-p53 inhibitor). While the data show promising efficacy signals (e.g., 91.3% CCyR rate for olverembatinib in CP-CML, 30% ORR for alrizomadlin combination in pediatric sarcomas), all three candidates remain investigational in the US and the press release contains no financial data, regulatory approvals, or guidance changes. The event is a routine scientific update with no material financial impact.
Key Facts
- Six abstracts selected for 2026 ASCO Annual Meeting (May 29–June 2, 2026), including three rapid oral presentations and three poster presentations.
- Olverembatinib (HQP1351) phase Ib data in Ph+ BCP-ALL/CML-LBP: 4 of 5 MRD+ patients achieved CR, 2 achieved MRD negativity.
- Olverembatinib second-line CP-CML data: 91.3% CCyR rate and 60.9% MMR rate at cycle 24 among 42 evaluable patients.
- Alrizomadlin (APG-115) ± lisaftoclax (APG-2575) in pediatric sarcomas: 30% ORR and 80% DCR in combination group; one CR in monotherapy.
- Olverembatinib in SDH-deficient GIST: 23.1% PR rate, median PFS 25.7 months (n=26).
- POLARIS-2 (olverembatinib phase 3 in CML) and GLORA (lisaftoclax phase 3 in CLL/SLL) are ongoing global registrational trials.
- All three drug candidates remain investigational in the US; no FDA approvals or regulatory decisions announced.
- No financial data, revenue, EPS, guidance, or deal values were disclosed in the press release.
Financial Impact
No financial impact disclosed; the press release contains only clinical data updates with no revenue, earnings, or guidance figures.
Risk Factors
- All three drug candidates are investigational in the US; FDA approval is not guaranteed and timelines are uncertain.
- Phase 3 trials (POLARIS-2, GLORA) may fail to meet endpoints, which would severely impact valuation.
- No financial data in this release; the company's cash runway and revenue trajectory remain unaddressed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3299861 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 6-K | $15.44 $15.45 | ▲ +0.06% | ▼ −0.65% | $15.44 (−0.00%) |
Oct 21, 2026 5d ago | 6-K | $14.92 $15.44 | ▲ +3.49% | ▲ +4.01% | $15.44 (+3.49%) |
Oct 15, 2026 11d ago | 6-K | $14.69 $15.37 | ▲ +4.63% | ▲ +5.74% | $15.44 (+5.11%) |
Sep 17, 2026 5w ago | 6-K | $15.37 $15.06 | ▲ +2.02% | ▲ +1.90% | $15.44 (−0.46%) |
Aug 19, 2026 9w ago | Press Release | $17.32 $17.00 | ▲ +1.85% | ▲ +2.26% | $15.44 (+10.85%) |
Aug 5, 2026 11w ago | 6-K | $16.86 $17.09 | ▲ +1.39% | ▲ +1.55% | $15.44 (−8.40%) |
Aug 3, 2026 12w ago | 6-K | $16.81 $16.69 | ▼ −0.68% | ▼ −2.49% | $15.44 (−8.12%) |
Jul 26, 2026 13w ago | Press Release | $18.89 $18.29 | ▼ −3.20% | ▼ −3.44% | $15.44 (−18.26%) |
Jul 20, 2026 14w ago | 6-K | $18.37 $19.10 | ▲ +3.97% | ▲ +3.14% | $15.44 (−15.95%) |
Jul 13, 2026 15w ago | 6-K | $19.24 $20.18 | ▲ +4.89% | ▲ +4.49% | $15.44 (−19.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers